ArticleProtein expression and purification2025
A direct solubilization approach to purify active full-length human neuropathy target esterase.
Article in Protein expression and purification, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Compound Heterozygous Variants in the Phospholipase Gene PNPLA6 Cause Hypopituitarism and Vision Loss.Human mutation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
PNPLA6 encodes neuropathy target esterase (NTE), a membrane-associated protein located in the endoplasmic reticulum and highly expressed in the developing and adult human brain and eye. Although research has uncovered the biochemical and cellular roles NTE plays in the cell, it is still unclear how NTE enzymatic activity causes defects in affected tissue, and how the structure of the protein modulates enzyme activity. Furthermore, full-length NTE has yet to be purified, which would be essential for future therapies such as enzyme replacement therapy. To address this, we developed a procedure to robustly express human full-length NTE in human suspension cell culture. This procedure expressed wild type NTE, variant PNPLA6 constructs, and N- and C-terminal tagged full-length constructs. Extraction and purification of NTE from native membranes was accomplished by synthetic nanodiscs, with CyclAPol C8-C0-50 able to solubilize and retain the activity of the full-length protein. This purified product produced homogenous populations of NTE under electron microscopy by negative staining. Overall, we provide a blueprint for large-scale expression and purification of a membrane-associated protein that is critical for studying NTE's structure and function in human disease, including therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.